CoChat

Medicare Part D Coverage of Antiobesity Medications — Challenges and Uncertainty Ahead

Baig, Khrysta, Dusetzina, Stacie B., Kim, David D., Leech, Ashley A. · 2023 · New England Journal of Medicine

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Interview with Dr. Ashley Leech on the potential implications of Medicare Part D covering medications for obesity treatment. (11:22)Download Medicare could soon be compelled to cover antiobesity medications, which intensifies the need to address questions of effectiveness and cost among its beneficiaries.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmp2300516

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 3 references

Research works printed but not linked: 1

  1. Atlas SJ Kim K Beinfeld M et al. Obesity management: an assessment of subcutaneous semaglutide phentermine/topiramate and naltrexone/bupropion. Boston: Institute for Clinical and Economic Review October 20 2022 (https://icer.org/assessment/obesity-management-2022/).

Cited by

Metadata

Authors
Baig, K., Dusetzina, S. B., Kim, D. D., & Leech, A. A.
Affiliations
Vanderbilt University (US)
Venue
New England Journal of Medicine
Published
2023-03-16
Volume
388
Issue
11
Pages
961-963
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4323925813
Cited by
66
References
3
Citations by year
2026: 7 · 2025: 16 · 2024: 26 · 2023: 17
FWCI
10.30
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords
Medicare Part D, anti-obesity drugs, obesity treatment, drug coverage, drug effectiveness, Medicare beneficiaries
MeSH terms
Aged, Humans, United States, Anti-Obesity Agents, Insurance Coverage, Uncertainty, Medicare Part D

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.